Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, Imayama S, Kato M, Hasebe I, Taira K, Yamamoto M, Mihara R, Kabashima K, Ruzicka T, Hanifin J, Kumagai Y. Nemoto O, et al. Among authors: matsuki s. Br J Dermatol. 2016 Feb;174(2):296-304. doi: 10.1111/bjd.14207. Epub 2015 Dec 19. Br J Dermatol. 2016. PMID: 26409172 Clinical Trial.
A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.
Matsuguma K, Matsuki S, Sakamoto K, Shiramoto M, Nakagawa M, Kimura M, Irie S, Kaneko D, Ohnishi A. Matsuguma K, et al. Among authors: matsuki s. Clin Pharmacol Drug Dev. 2015 Mar;4(2):99-104. doi: 10.1002/cpdd.178. Epub 2015 Jan 22. Clin Pharmacol Drug Dev. 2015. PMID: 27128214 Clinical Trial.
Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Shiomi M, Matsuki S, Ikeda A, Ishikawa T, Nishino N, Kimura M, Kumagai Y, Irie S. Shiomi M, et al. Among authors: matsuki s. Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):218-25. doi: 10.1002/cpdd.164. Epub 2014 Oct 27. Clin Pharmacol Drug Dev. 2015. PMID: 27140802 Clinical Trial.
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.
Sakamoto K, Matsuki S, Irie S, Uchida N, Hayashi N, Horiuchi M, Ren S. Sakamoto K, et al. Among authors: matsuki s. Clin Pharmacol Drug Dev. 2020 Oct;9(7):833-840. doi: 10.1002/cpdd.775. Epub 2020 Jan 20. Clin Pharmacol Drug Dev. 2020. PMID: 31960624 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects.
Matsuguma K, Matsuki S, Eunhee C, Watanabe A, Tanaka A, Sakamoto K, Takeshita H, Hitaka A, Shigetome K, Kimura M, Miyamoto A, Irie S, Kaneko D, Ohnishi A. Matsuguma K, et al. Among authors: matsuki s. Drug Dev Ind Pharm. 2015 Mar;41(3):470-5. doi: 10.3109/03639045.2013.879721. Epub 2014 Jan 28. Drug Dev Ind Pharm. 2015. PMID: 24471477 Clinical Trial.
Cerebrospinal Fluid Protein Concentration in Healthy Older Japanese Volunteers.
Yoshihara T, Zaitsu M, Ito K, Hanada R, Chung E, Yazawa R, Sakata Y, Furusho K, Tsukikawa H, Chiyoda T, Matsuki S, Irie S. Yoshihara T, et al. Among authors: matsuki s. Int J Environ Res Public Health. 2021 Aug 17;18(16):8683. doi: 10.3390/ijerph18168683. Int J Environ Res Public Health. 2021. PMID: 34444430 Free PMC article.
187 results